A scoping review of 28 studies suggests that GLP-1 receptor agonists may improve androgen levels and menstrual function in women with polycystic ovary syndrome (PCOS), alongside their established metabolic benefits. Evidence for improved ovulation, fertility, and pregnancy outcomes remains limited, and the researchers could not determine whether reproductive benefits result directly from the drugs or from weight loss and improved metabolic health.